Such an example is vemurafenib, a BRAF inhibitor and a standard treatment option for patients with BRAFV600E mutant melanoma or NSCLC, which is not efficient at least as monotherapy in patients with BRAFV600E mutant CRC (42). This evidence concerns the gene BRAF and colorectal carcinoma.